Lucid Operating Margin from 2010 to 2026
| LUCD Stock | USD 1.25 0.03 2.34% |
Check Lucid Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lucid Diagnostics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 997.8 K, Interest Expense of 28.4 K or Selling General Administrative of 24.3 B, as well as many indicators such as Price To Sales Ratio of 10.4, Dividend Yield of 0.0 or PTB Ratio of 7.25. Lucid financial statements analysis is a perfect complement when working with Lucid Diagnostics Valuation or Volatility modules.
Lucid | Operating Margin | Build AI portfolio with Lucid Stock |
Analyzing Lucid Diagnostics's Operating Margin over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Margin has evolved provides context for assessing Lucid Diagnostics's current valuation and future prospects.
Latest Lucid Diagnostics' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Lucid Diagnostics over the last few years. It is Lucid Diagnostics' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lucid Diagnostics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (9.71) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Lucid Operating Margin Regression Statistics
| Arithmetic Mean | (50.42) | |
| Coefficient Of Variation | (62.26) | |
| Mean Deviation | 17.83 | |
| Median | (54.84) | |
| Standard Deviation | 31.39 | |
| Sample Variance | 985.54 | |
| Range | 139 | |
| R-Value | 0.29 | |
| Mean Square Error | 962.03 | |
| R-Squared | 0.08 | |
| Significance | 0.26 | |
| Slope | 1.81 | |
| Total Sum of Squares | 15,769 |
Lucid Operating Margin History
About Lucid Diagnostics Financial Statements
Lucid Diagnostics stakeholders use historical fundamental indicators, such as Lucid Diagnostics' Operating Margin, to determine how well the company is positioned to perform in the future. Although Lucid Diagnostics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Lucid Diagnostics' assets and liabilities are reflected in the revenues and expenses on Lucid Diagnostics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Lucid Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:Check out the analysis of Lucid Diagnostics Correlation against competitors. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Will Health Care Equipment & Supplies sector continue expanding? Could Lucid diversify its offerings? Factors like these will boost the valuation of Lucid Diagnostics. Expected growth trajectory for Lucid significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lucid Diagnostics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.77) | Revenue Per Share | Quarterly Revenue Growth 0.033 | Return On Assets | Return On Equity |
Understanding Lucid Diagnostics requires distinguishing between market price and book value, where the latter reflects Lucid's accounting equity. The concept of intrinsic value - what Lucid Diagnostics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Lucid Diagnostics' price substantially above or below its fundamental value.
Understanding that Lucid Diagnostics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lucid Diagnostics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Lucid Diagnostics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.